All In Biotech

Drug Trial Radar · NCT06838143

Ilaris NIS in Korea

Real Life Non-interventional Study on Safety and Effectiveness of Ilaris® (Canakinumab) 150 mg for Subcutaneous Injection in Hereditary Periodic Fever Syndrome (CAPS, crFMF, TRAPS and HIDS/MKD) Patients and sJIA Patients (REASSURE)

Last checked: Nov 20, 2026Latest source record: May 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

25

Planned (sponsor's estimate)

Start

Mar 29, 2025

Primary completion

Sep 30, 2028

Study completion Sep 30, 2028

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Feb 20, 2025

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 2 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to evaluate safety and effectiveness of Ilaris in adult and pediatric patients receiving the drug in a clinical setting for any of the following indications, Hereditary Periodic Fever Syndromes, Cryopyrin-associated periodic syndromes (CAPS), colchicine resistance familial Mediterranean fever (crFMF), TNF receptor associated periodic syndrome (TRAPS), Hyper-IgD syndrome / Mevalonate kinase deficiency (HIDS/MKD) or Systemic juvenile idiopathic arthritis (sJIA).

Conditions

  • Hereditary Periodic Fever Syndromes
  • Cryopyrin-associated Periodic Syndromes (CAPS)
  • Colchicine Resistance Familial Mediterranean Fever (crFMF)
  • TNF Receptor Associated Periodic Syndrome (TRAPS)
  • Hyper-IgD Syndrome / Mevalonate Kinase Deficiency (HIDS/MKD)
  • Systemic Juvenile Idiopathic Arthritis (sJIA)

Interventions

  • IlarisBiological

    Prospective observational study. There is no treatment allocation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events and serious adverse eventsTime frame: Up to 104 weeks from Ilaris treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.